<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3596">
  <stage>Registered</stage>
  <submitdate>11/07/2012</submitdate>
  <approvaldate>11/07/2012</approvaldate>
  <nctid>NCT01646567</nctid>
  <trial_identification>
    <studytitle>SHP-141C in Plaque Type Psoriasis</studytitle>
    <scientifictitle>A Double-Blind, Within-Subject Randomised, Placebo-Controlled, Proof of Concept, Comparison Study of SHP-141C Topical Cream in Psoriasis, Using the Microplaque Assay.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SHP-141C-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Plaque Type Psoriasis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SHP-141C
Treatment: drugs - Placebo to SHP-141C
Treatment: drugs - Betamethasone Valerate
Treatment: drugs - Calcipotriol

Experimental: SHP-141C &amp; Placebo &amp; Calcipotriol &amp; Betamethasone Valerate - A 100 mg dose of SHP-141C cream at three concentrations (0.5%, 1.0% and 2.0%), a matched placebo cream and two reference treatments: Calcipotriol 0.005% cream and Betamethasone Valerate 0.02% cream, applied topically to a selected plaque on each subject, six times per week over 28 days for a total of 24 doses.


Treatment: drugs: SHP-141C
Topical Cream

Treatment: drugs: Placebo to SHP-141C
Placebo Topical Cream

Treatment: drugs: Betamethasone Valerate
Topical cream, 0.02%

Treatment: drugs: Calcipotriol
Topical cream, 0.005%

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in Local Plaque Severity Index (LPSI) - Measurement of plaque severity including erythema, induration, and desquamation.</outcome>
      <timepoint>Baseline, day 15, day 33</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The number of patients with adverse events - Adverse event data for each subject will be collected.</outcome>
      <timepoint>daily to and including Day33</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Mild to moderate chronic plaque-type psoriasis.

          2. psoriasis of at least one year.

          3. Stable disease for at least two weeks prior to the commencement of study treatment.

          4. One nominated target lesions must have areas of at least 86 x 57 mm2.

          5. BMI of less than 35 kg/m2. -</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Dermatological Conditions

               -  Subjects with erythrodermic, guttate, palmar, plantar or generalised pustular
                  forms of psoriasis.

               -  Subjects with scalp, palmar or plantar psoriasis only.

               -  Subjects with any skin condition other than psoriasis, in particular eczema,
                  cutaneous infections, significant sun damage or an inherited skin disorder (other
                  than psoriasis).

          2. Concurrent Medical Conditions

               -  History of clinically significant intercurrent disease of any type (other than
                  psoriasis).

               -  A history of moderate or severe asthma during the last 10 years.

               -  Major chronic inflammatory disease .

               -  Congenital immunodeficiency or cancer prone syndrome.

               -  History of abnormal bleeding tendencies or thrombophlebitis, or a history of
                  Hepatitis B, Hepatitis C or HIV infection.

               -  History of malignancy (other than adequately treated skin carcinoma or
                  carcinoma-in-situ of the cervix).

          3. Laboratory Status

               -  Any evidence of organ dysfunction, which is confirmed on re-examination to be
                  clinically significant (i.e. in the opinion of the Medical Officer would
                  jeopardise the safety of the subject or impact on the validity of the study
                  results),

               -  A creatinine clearance of less than 75 mL/min.

               -  Liver function test &gt; 1.5 x upper limit of normal other than an isolated
                  bilirubin.

               -  Hepatitis B surface antigen, Hepatitis C antibody, HIV antibodies.

          4. Treatment with any of the following within 4 weeks prior to the commencement of study
             treatment and for the duration of the study:

               -  Systemic retinoids.

               -  Immunosuppressant agents (e.g. methotrexate, cyclosporine, azathioprine,
                  thioguanine prednisone, prednisolone, hydroxyurea or mycophenolate mofetil).

               -  Phototherapy or photochemotherapy.

               -  High potency topical corticosteroids.

               -  "Alternative medicine" treatments for psoriasis.

               -  Prolonged sun exposure or tanning bed use, which may in the opinion of the
                  Investigator, modify disease activity.

          5. Topical treatment of the 2 target lesions with any of the following within 2 weeks
             prior to commencement of study treatment and for the duration of the study

               -  Moderate potency topical corticosteroids.

               -  Vitamin D analogues and topical retinoids.

               -  Keratolytics, coal tar and dithranol.

          6. Concurrent Medications Subjects have received or anticipate receiving a new medicine
             (prescription, over-the-counter or herbal), given systemically or topically, within 14
             days prior to the start of dosing. Subjects may be enrolled if stable on existing
             therapy (having been on it for at least 60 days) as determined by the Principal
             Investigator.

          7. Hypersensitivity History of allergy and/or hypersensitivity to any of the stated
             ingredients of the formulations or other topical agents. A known hypersensitivity to
             lignocaine, or all surgical dressings that may be used in the study procedures.

          8. Females who are lactating, pregnant or planning to become pregnant.

          9. Drug and Alcohol Abuse History of, or current evidence of, abuse of alcohol or any
             drug substance, licit or illicit, or positive urine drug and alcohol screen for drugs
             of abuse and alcohol.

         10. Psychiatric Disorder History of any psychiatric illness which may impair the ability
             to provide written informed consent

         11. Participation in a research study within 30 days of the start of dosing.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>14</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network Limited - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>TetraLogic Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the safety, tolerability and clinical activity of the
      SHP-141C topical cream formulations in patients with plaque type psoriasis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01646567</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Foley</name>
      <address>The Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>